Can Cancer Advances Save Kennedy?

When the Wilson family found out that Sen. Ted Kennedy had been diagnosed with brain cancer, they sent him an optimistic note.

"I just wanted him to know that there is some hope," said Marty Wilson, 55, whose mother, Cleora, was diagnosed with brain cancer two years ago. "Though it's not curable, it is treatable."

The note may be a poignant reminder that Kennedy is not alone with his disease. Doctors diagnose about 180,000 new cases of brain cancers each year. Of those, gliomas are the most common type of brain tumor, and malignant gliomas are the most aggressive -- and deadly.

For any patient, such a diagnosis would be devastating and Kennedy has not always had a clean bill of health. Just six months ago, he had surgery to correct a narrowed carotid artery.

At 76 years old, he is also among the older patients with this condition -- which, like many medical conditions, has been known to carry a worse prognosis with increasing age.

Still, cancer experts are not concerned that Kennedy will be precluded from potentially promising new treatments because of his age or his medical history -- which ultimately means that the decision will probably be the senator's when it comes to his course of treatment.

Past Patients May Suggest Promise for Kennedy's Case

Cleora Wilson, 76, has more in common with Kennedy than her age. She also had a malignant glioma and underwent surgery to remove it, followed by radiation and chemotherapy.

But this traditional treatment for brain cancer had limitations. If a surgeon tried to remove a brain tumor completely, the procedure would also remove precious neurons and brain cells that continue to help the body function normally. Radiation and chemotherapy, while they can be effective at killing cancer cells, are also effective at killing healthy cells.

"These drugs are nonspecific poisons," said Dr. Howard Fine, chief of the neuro-oncology branch at the National Cancer Institute, adding that they can be like setting off bombs. "You hope that when the smoke clears that the bad guys are dead and the good ones are still standing."

But the Wilsons refused to settle for just the conventional treatment and the 15-month life sentence the doctors gave Cleora. She chose to receive experimental treatments that would help shrink the tumor and prevent it from growing large again -- and it worked.

Experimental treatments for brain cancer are a promising frontier for patients. Where surgery and radiation stop working effectively, these treatments begin.

Targeted Therapy

Newer, experimental therapies are like smart bombs, Fine said, because they have the potential to target cancer cells and destroy them -- or at least hold them in check -- without destroying other brain cells.

The most promising therapies and those with the best track record are known as small molecule therapies. These treatments involve drugs that inhibit crucial cellular growth processes. Cleora Wilson received Avastin, a drug that prevents her tumor cells from growing blood vessels with which to nourish themselves.

Though Avastin is not yet approved by the Food and Drug Administration for treating brain cancer, it has been approved for treating colon, breast and some types of lung cancer.

Targeted molecular therapies have strong potential for advancement because they can be used for a wide variety of cellular pathways to prevent tumor growth, depending on the person being treated.

Page
  • 1
  • |
  • 2
Join the Discussion
You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.
blog comments powered by Disqus
 
You Might Also Like...
See It, Share It
PHOTO: Ebola patients Nina Pham, left, Dr. Craig Spencer, center, and Amber Vinson are seen in undated file photos.
Courtesy Pham Family | LinkedIn | Obtained by ABC
PHOTO: Television personalities Mama June and Honey Boo Boo are seen in this, June 11, 2014, file photo.
Douglas Gorenstein/NBCU Photo Bank/Getty Images
PHOTO: A New York City subway train is pictured in this stock image.
Andrew A. Smith/Getty Images